First ‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China

ConclusionOur study shows that for advanced NS ‐NSCLC patients with wild‐type driver genes, first‐line PemPBev might be a better treatment option compared to PacCBev.

Source: Thoracic Cancer - March 21, 2019 Category: Cancer & Oncology Authors: Qing Chang, Yanwei Zhang, Jianlin Xu, Runbo Zhong, Huiping Qiang, Bo Zhang, Baohui Han, Jialin Qian, Tianqing Chu Tags: ORIGINAL ARTICLE Source Type: research